Cargando…

Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report

BACKGROUND: The emergence of secondary drug resistance when treating epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) using EGFR-tyrosine kinase inhibitors (EGFR-TKIs), seriously affects the therapeutic efficacy and survival of patients. Here, we report a case of ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Er, Chen, Xi-Er, Mao, Jia, Zhou, Jing-Jing, Chen, Ling, Xu, Jia-Yi, Tao, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968804/ https://www.ncbi.nlm.nih.gov/pubmed/35434119 http://dx.doi.org/10.12998/wjcc.v10.i9.2836

Ejemplares similares

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
por: Su, Kang-Yi, et al.
Publicado: (2018)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
por: Mäkinen, Netta, et al.
Publicado: (2021)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
por: Haratake, Naoki, et al.
Publicado: (2020)

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
por: Kimura, Hideharu, et al.
Publicado: (2019)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
por: Zheng, Lin-Peng, et al.
Publicado: (2018)

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
por: Sakai, Hitomi, et al.
Publicado: (2017)

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma
por: Hakozaki, Taiki, et al.
Publicado: (2020)

T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review
por: Kusaba, Yusaku, et al.
Publicado: (2022)

A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies
por: Wang, Jing, et al.
Publicado: (2021)

The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
por: Tseng, Jeng-Sen, et al.
Publicado: (2016)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report
por: Miyazaki, Shinichi, et al.
Publicado: (2020)

Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
por: Zhang, Xiaoying
Publicado: (2021)

In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations
por: Zang, Shu-Zhi, et al.
Publicado: (2017)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
por: Gao, Xuejuan, et al.
Publicado: (2019)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
por: Han, Xiaoyu, et al.
Publicado: (2021)

Unusual metachronous lung adenocarcinomas harboring EGFR L858R/T790M mutations: A case report
por: Pei, Guotian, et al.
Publicado: (2020)

EGFR T790M-Positive Lung Adenocarcinoma Metastases to the Pituitary Gland Causing Adrenal Insufficiency: A Case Report
por: Adashek, Michael L., et al.
Publicado: (2018)

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report
por: Ma, Shuxiang, et al.
Publicado: (2020)

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial–mesenchymal transition
por: Liu, Kejun, et al.
Publicado: (2021)

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

EGFR-T790M Mutation–Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
por: Wu, Pei-Shan, et al.
Publicado: (2023)

Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report
por: Nishioka, Naoya, et al.
Publicado: (2018)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
por: Joshi, Asim, et al.
Publicado: (2022)

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies
por: Miura, Satoru, et al.
Publicado: (2022)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Application value of CT radiomic nomogram in predicting T790M mutation of lung adenocarcinoma
por: Li, Xiumei, et al.
Publicado: (2023)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
por: Zhang, Nana, et al.
Publicado: (2017)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
por: Vaclova, Tereza, et al.
Publicado: (2021)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
por: Masuda, Takeshi, et al.
Publicado: (2023)

The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
por: Pan, Guoqiang, et al.
Publicado: (2021)

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2018)

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
por: Wang, Shuhang, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vc8qs7ihmfovpi0lr27oqgpoop